Non-valvular atrial Fibrillation Patients with Chronic Kidney Diseases
Conditions
Interventions
rivaroxaban group
warfarin group
Sponsors
Saga University Faculty of Medicine, Department of Cardiovascular Medicine
Kameda Medical Center Tokyo Metropolitan Hiroo Hospital Dokkyo Medical University Saitama Medical Center Yokohama Minami Kyousai Hospital Imari Arita Kyoritsu Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria (1)Age>- 30 years old. (2)Patients who had initiated anticoagulation therapy or patients who had already received warfarin therapy. (3)estimated glomerular filtration rate > 30 and < 60 mL/min/1.73 m2: CKD grade G2 to G3b.
Exclusion criteria
Exclusion criteria: Patients meeting any of the following criteria were not eligible for inclusion in this study. (1)Patients with onset of acute coronary syndrome or stroke within 6 months. (2)Patients scheduled to undergo percutaneous coronary intervention (PCI) or catheter ablation. (3)Patients receiving dual ntiplatelet therapy (DAPT). (4)Patients with a history of hypersensitivity to the components of warfarin or rivaroxaban. (5)Patients with active bleeding (non-major clinically relevant bleeding events, such as intracranial hemorrhage, gastrointestinal hemorrhage). (6)Patients with hepatic disorders associated with coagulation abnormalities. (7)Patients with moderate or severe hepatic disorder (equivalent to Child-Pugh classification B or C). (8)Patients with renal failure (creatinine clearance < 30 mL/min). (9)Pregnant women or women with pregnancy potential. (10)Patients receiving HIV protease inhibitors (ritonavir, atazanavir, indinavir, etc.). (11)Patients receiving oral or intravenous administration of azole antifungal drugs (itraconazole, voriconazole, or ketoconazole). (12)Patients receiving vitamin K agents for osteoporosis. (13)Patients receiving iguratimod. (14)Patients with acute bacterial endocarditis. (15)Patients who did not give informed consent. (16)Other patients considered by the investigator to be unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint was the change amount in urinary albumin 3 months after registration. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoints were changes amount in endothelial functions, inflammatory markers, renal function markers, osteocalcin markers. | — |
Countries
Japan
Contacts
Public ContactKoichi Node
Saga University Faculty of Medicine Department of Cardiovascular Medicine
Outcome results
None listed